{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "BLLN",
  "name": "BillionToOne, Inc.",
  "url": "https://frontierpicks.com/dossiers/BLLN/",
  "json_url": "https://frontierpicks.com/dossiers/BLLN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "BillionToOne's prenatal and cancer testing business is growing 64% a year and is profitable, and the shares have rebounded to $111.47; the 4 November 2026 third-quarter report decides whether results confirm the move.",
  "invalidation_trigger": "A daily close below $81.84, the start-of-2026 level; a full-year revenue guidance cut below the $450 million floor would separately break the operating case.",
  "catalyst_date": "2026-11-04",
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Executive insider sales are made under pre-arranged Rule 10b5-1 trading plans, so Form 4 sales recur on a schedule regardless of price or news.",
    "CMS 2027 clinical laboratory fee changes reported on 2026-09-23 are preliminary; final rates and their revenue effect for BillionToOne have not been published.",
    "BillionToOne listed on Nasdaq in late 2025, so its trading history is short and moving averages and ranges cover less than two years."
  ],
  "source_links": [],
  "body_markdown": "## Current Thesis\nBillionToOne's prenatal and cancer testing business is growing 64% a year and is profitable, and the shares have bounced back to $111.47 (close, 2026-10-26) from $94.44 on 2026-10-13. The third-quarter report on 2026-11-04, after the market close, decides whether revenue and margin justify the rebound. Until it arrives the shares look about as likely to lag the S&P 500 as to lead it, so the rating stays at the low end.\n\nThe price is 25.7% below the $149.97 52-week high and down 15.9% over three months, per adjusted daily closes. The 14-day relative strength index is 64.5, up from 32 on 2026-10-13. The close sits above the 50-day moving average of $106.67 and the 200-day of $100.31 that MarketBeat reported on 2026-10-06. Both averages have moved since then, so the exact gap is not known.\n\nThe business record has not changed since the second-quarter report of 2026-08-05: revenue of $109.4 million, up 64% year over year, operating income of $5.5 million, and full-year revenue guidance of $450–465 million. The narrative is maturing: coverage is wide, with Guggenheim lifting its target to $128 on 2026-10-01, and the 2026-10-14 announcement of the report date is the only company event since the last note.\n\n## Bull Case\n- **Revenue is growing with test volume.** The 2026-08-05 report showed 196,000 second-quarter tests delivered, up 35% year over year, and revenue up 64% to $109.4 million. Operating income of $5.5 million means the growth is profitable.\n- **Oncology is small but compounding fast.** Second-quarter oncology revenue was $13.7 million, up 176% year over year, per the company's results release. On 2026-10-07 the company reported a peer-reviewed study in which its tissue-free Northstar Response test matched a tumor-informed circulating tumor DNA test on tumor-burden direction in 67 of 71 sequential pairs (94%).\n- **Analyst targets sit well above the price.** MarketBeat listed a consensus target of $126.25 on 2026-10-06, from 7 Buy, 3 Hold and 1 Sell ratings. Guggenheim's target is $128 (2026-10-01), Canaccord Genuity initiated at Buy with a $120 target (2026-09-02), and JPMorgan and BTIG both sit at $130 (2026-08-06).\n- **Medicare repricing was reported as favourable.** Benzinga reported on 2026-09-23 that the preliminary 2027 Centers for Medicare & Medicaid Services (CMS) clinical lab fee update brought positive changes for BillionToOne tests. The dollar effect has not been quantified.\n\n## Bear Case\n- **The recovery is recent and unconfirmed by results.** The shares closed at $94.44 on 2026-10-13 and $111.47 on 2026-10-26, with no new financial results in between. The next filed numbers arrive on 2026-11-04.\n- **Insider supply continues.** CTO David Tsao sold 20,000 shares on 2026-10-05 at a weighted average of $108.39 under a Rule 10b5-1 plan adopted 2026-06-05, per his Form 4. A Form 4 for SVP John Roderick ten Bosch shows sales on 2026-10-05 at $105.15, and company news on 2026-10-19 reported further insider sales. MarketBeat counted 216,357 shares, about $24.6 million, sold by insiders over the 90 days to 2026-10-06.\n- **The valuation leaves little room for a miss.** At the $98.09 close on 2026-10-09 the market value was $4.63 billion, about 11.3 times sales, per Gotrade. At the higher $111.47 close the multiple is larger. A 5% operating margin in the second quarter gives little room for higher spending or a revenue shortfall.\n- **The September–October drop had no identified cause.** No company news explained the declines of 2026-09-30 and 2026-10-06, and a move with no stated cause can reverse as quickly as the rebound did.\n\n## Setup & Price Structure\nThe adjusted daily closes show a fall from the $149.97 52-week high to $94.44 on 2026-10-13, then a rise to $111.47 on 2026-10-26. The shares have a short trading history since the late-2025 Nasdaq listing, so the 200-day average and the 52-week range cover less than two years.\n\nThe prior $100–110 area, where insiders sold on 2026-10-05, is the zone the shares are now trading through. The 2026-10-13 close of $94.44 is the recent low. The invalidation level at $81.84 is the start-of-year close.\n\nCrowding evidence is limited to three observable items: an earnings report nine days away, recurring insider sales under 10b5-1 plans, and a relative strength reading of 64.5 after a sharp two-week rise.\n\n## Catalyst Calendar (next 30 days)\n- The report tests the $450–465 million full-year revenue guidance, oncology growth and the thin operating margin.\n- **Through November, dates not set:** Further Form 4 filings from executives selling under 10b5-1 plans.\n- **Later, date not announced:** Final CMS 2027 clinical lab fee rates, which would settle whether the preliminary changes benefit BillionToOne's revenue.\n\n## What Would Change Our Mind\nThe operating case breaks if the third-quarter report cuts full-year revenue guidance below the $450 million floor, or shows an operating loss after the $5.5 million operating profit of the second quarter. Slower oncology growth than the 176% of the second quarter would weaken the main growth argument.\n\nThe price case breaks on a daily close below $81.84, the start-of-year level. A final CMS fee schedule that reverses the preliminary changes would remove one of the supports of the bull case. A strong report, with revenue growth near 64% and a profitable quarter, would show results confirming the rebound and would move the rating up.\n\n## Correlation Notes\nBillionToOne trades with other recently listed growth diagnostics and genomic testing companies, and with small- and mid-cap healthcare shares more broadly. CareDx was named alongside it in the Benzinga report of 2026-09-23 on Medicare lab fees, so lab-payment news can move both. The shares have no current theme cluster that explains the September–October swings.",
  "first_seen": "2026-09-27",
  "last_analyzed": "2026-10-27T05:04:21+00:00",
  "last_synthesized": "2026-10-27",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}